Matinas BioPharma Holdings (MTNB) Non-Current Deferred Tax Liability (2015 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Non-Current Deferred Tax Liability of $257000.0 for Q1 2026, little changed year-over-year from $257000.0 in Q1 2025, and little changed quarter-over-quarter from $257000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Non-Current Deferred Tax Liability (2015 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Non-Current Deferred Tax Liability for 12 consecutive years, with $257000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $257000.0; the TTM figure through Mar 2026 stood at $257000.0 (changed 0.0% YoY), while the FY2025 annual figure was $257000.0, changed 0.0% from the prior year.
- Non-Current Deferred Tax Liability steadied at $257000.0 in Q1 2026 per MTNB's latest filing, from $257000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $341265.0 in Q1 2022 and bottomed at $257000.0 in Q4 2024.
- Historically, Non-Current Deferred Tax Liability has averaged $311399.7 across 5 years, with a median of $341000.0 in 2022.
- Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability changed 0.0% — and 2024, when it fell 24.63%.
- Matinas BioPharma Holdings' Non-Current Deferred Tax Liability stood at $341000.0 in 2022, then changed by 0.0% to $341000.0 in 2023, then dropped by 24.63% to $257000.0 in 2024, then changed by 0.0% to $257000.0 in 2025, then changed by 0.0% to $257000.0 in 2026.
- Business Quant data shows MTNB's Non-Current Deferred Tax Liability at $257000.0 in Q1 2026, $257000.0 in Q4 2025, and $257000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 257,000.00 |
| Jun 30, 2026 | 257,000.00 |
| Mar 31, 2026 | 257,000.00 |
| Mar 31, 2026 | 257,000.00 |
| Dec 31, 2025 | 257,000.00 |
| Dec 31, 2025 | 257,000.00 |
| Sep 30, 2025 | 257,000.00 |
| Sep 30, 2025 | 257,000.00 |
| Jun 30, 2025 | 257,000.00 |
| Jun 30, 2025 | 257,000.00 |
| Mar 31, 2025 | 257,000.00 |
| Mar 31, 2025 | 257,000.00 |
| Dec 31, 2024 | 257,000.00 |
| Dec 31, 2024 | 257,000.00 |
| Sep 30, 2024 | 341,000.00 |
| Sep 30, 2024 | 341,000.00 |
| Jun 30, 2024 | 341,000.00 |
| Jun 30, 2024 | 341,000.00 |
| Mar 31, 2024 | 341,000.00 |
| Mar 31, 2024 | 341,000.00 |